Page 1

JANUX Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results -Company remains on - track to submit IND filings for two programs in 2022- -Board of Directors strengthened with key appointments- - $ 387.5 million in cash and cash equivalents and short - term investments at end of third quarter 2021- Exhibit 99.1 SAN DIEGO , November 9 , 2021 – Janux Therapeutics , Inc. ( Nasdaq : JANX ) ( Janux ) , a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager ( TRACTr ) and Tumor Activated Immunomodulator ( TRACIr ) platforms , today reported financial results for the quarter ended September 30 , 2021 . “ In the third quarter , we continued to utilize our novel TRACTr and TRACIr platforms to advance our pipeline of next generation immunotherapies . We remain on - track to execute key milestones , including two IND submissions next year for our PSMA - TRACTr and EGFR - TRACTr candidates , ” said David Campbell , Ph.D. , President and CEO of Janux . “ Further , we welcomed Dr. Ron Barrett and Alana McNulty to Janux's Board of Directors . These two key leadership additions bring important expertise to the company as we work to advance our programs towards the clinic . " RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES : • TRACTr product candidates advancing as planned . Janux's lead TRACTr programs of next - generation T cell engagers remain on - track . 0 In the first half of 2022 , Janux expects to submit an Investigational New Drug ( IND ) application for its PSMA - TRACTr candidate , targeting prostate - specific membrane antigen ( PSMA ) . 0 In the second half of 2022 , Janux expects to submit an IND application for its EGFR - TRACTr candidate , targeting epidermal growth factor receptor ( EGFR ) . 0 In 2023 , Janux expects to submit an IND application for its TROP2 - TRACTr , targeting trophoblast cell surface antigen 2 ( TROP2 ) . • On track for selection of TRACIr development candidate in 2022 as planned . Janux is applying its TRACIr technology to develop a costimulatory bispecific product candidate against programmed death - ligand 1 ( PD - L1 ) and Cluster of Differentiation 28 ( CD28 ) to further enhance the anti - tumor activity of T cells . This will be Janux's first program derived from its TRACIr platform . • Strengthened Board of Directors with appointment of Ron Barrett , Ph.D. , and Alana McNulty . Dr. Barrett is a scientist entrepreneur with more than 30 years of experience in the biopharmaceutical industry as a co - founder and leader of biopharmaceutical companies and has been responsible for advancing research that led to FDA approval of three drugs . Ms. McNulty has more than 30 years of experience in finance and business development for private and publicly traded biopharmaceutical companies , playing a key role over her career in a breadth of strategic transactions .